Fig. 3

MEKi withdrawal from BRAF^V600E-amplified MEKi-resistant HT29 cells causes cell death. a HT29 and HT6244-R cells were treated with either 1 μM selumetinib (HT6244-R + Sel) or DMSO only (HT29, HT6244-R − Sel) and cell numbers counted over 10 days. Results are mean ± SD of cell culture triplicates, representative of two experiments. b, c HT29 and HT6244-R cells were treated with either 1 μM selumetinib (HT6244-R + Sel) or DMSO only (HT6244-R − Sel) for the indicated times, and cell cycle distribution determined by flow cytometry. d HT29 and HT6244-R cells were treated with 1 μM selumetinib (HT6244-R + Sel) or DMSO only (HT29, HT6244-R − Sel), with or without 10 μM Q-VD-OPh (Q-VD) for up to 12 days, and sub-G1 fraction determined by flow cytometry. P < 0.05 (*) determined by unpaired two-tailed t-test. e HT29 or HT6244-R cells were treated with 1 μM selumetinib (Sel; +) or DMSO only (−), with or without 0.1 μM SCH772984 (SCH) for 9 or 12 days, and sub-G1 fraction determined by flow cytometry. P < 0.001 (***) determined by one-way ANOVA with Tukey’s multiple comparisons test. b–e Results are mean ± SD of three independent experiments